Providers who order several tests are more likely to order low-value prostate cancer screening
TUESDAY, Jan. 10, 2023 (HealthDay News) — Low-value prostate cancer screening is common in primary care, according to a study published in the January issue of the Journal of the American Board of Family Medicine.
Chris Gillette, Ph.D., from the Wake Forest School of Medicine in Winston-Salem, North Carolina, and colleagues used data from the National Ambulatory Medicare Care Survey (2013 to 2016 and 2018) to assess the proportion of U.S. primary care visits at which low-value prostate cancer screening is ordered, as well as characteristics associated with low-value prostate cancer screening.
The researchers found 6.71 low-value prostate-specific antigens (PSAs) per 100 visits and 1.65 low-value digital rectal exams (DREs) per 100 visits. The odds of ordering a low-value PSA increased by 49 percent and the odds of performing a low-value DRE increased by 37 percent for each additional service ordered by primary care providers.
“As health care systems move toward a more value-based care system — where the benefit of services provided outweighs any risks — providers need to engage patients in these discussions on the complexity of this testing,” Gillette said in a statement. “Ultimately, when and if to screen is a decision best left between a provider and the patient.”
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
Machine Learning Model IDs Heart Failure With Reduced Ejection Fraction Using Routine Lab Indicators 
Addition of CAC to PREVENT-ASCVD Equations May Improve Predictive Utility in Certain Patients 
Risk for Prostate Cancer Elevated With Higher Ultraprocessed Food Intake 
Rates of Active Surveillance for Low-Risk Prostate Cancer High for Veterans 
Achieving PSA <0.2 ng/mL Improves Survival in Metastatic Castration-Sensitive Prostate Cancer 
Multivariable Risk Score Beneficial for Identifying Clinically Significant Prostate Cancer 
